Journal
EJHaem
Publication Date
11-1-2022
Volume
3
Issue
4
First Page
1346
Last Page
1351
Document Type
Open Access Publication
DOI
10.1002/jha2.591
Rights and Permissions
Pemmaraju N, Harrison C, Gupta V, Verstovsek S, Scott B, Oh ST, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Mesa R, Buckley S, Roman-Torres K, Vannucchi A, Yacoub A. Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. EJHaem. 2022 Oct 20;3(4):1346-1351. doi: 10.1002/jha2.591. © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Pemmaraju, Naveen; Harrison, Claire; Gupta, Vikas; Verstovsek, Srdan; Scott, Bart; Oh, Stephen T; Palandri, Francesca; Al-Ali, Haifa Kathrin; Sobas, Marta; McMullin, Mary Frances; Mesa, Ruben; Buckley, Sarah; Roman-Torres, Karisse; Vannucchi, Alessandro; and Yacoub, Abdulraheem, "Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis." EJHaem. 3, 4. 1346 - 1351. (2022).
https://digitalcommons.wustl.edu/oa_4/2548
Department
ICTS (Institute of Clinical and Translational Sciences)
